Loading...
•
Jun 30
ACADIA Q2 2025 Earnings Report
Acadia Pharmaceuticals reported its second quarter 2025 financial results, with total revenues increasing by 9% year-over-year, driven by strong sales of NUPLAZID and DAYBUE.
Key Takeaways
Acadia Pharmaceuticals delivered a strong second quarter in 2025, with total revenues reaching $264.6 million, a 9% increase year-over-year. Both NUPLAZID and DAYBUE showed significant sales growth, contributing to the positive financial performance. The company also highlighted progress in its R&D pipeline and key patent litigation wins.
Total revenues for Q2 2025 were $264.6 million, marking a 9% increase compared to the same period in the previous year.
NUPLAZID net product sales grew 7% year-over-year to $168.5 million, driven by strong commercial execution and increased patient engagement.
DAYBUE net product sales increased 14% year-over-year to $96.1 million, achieving its highest paid patient count to date.
Net income for the quarter was $26.7 million, or $0.16 per common share, compared to $33.4 million, or $0.20 per common share, in Q2 2024.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia Pharmaceuticals is raising the low end of its NUPLAZID net product sales guidance range for 2025, while reiterating all other prior 2025 guidance.
Positive Outlook
- Raised the low end of NUPLAZID net product sales guidance range to $665 million to $690 million.
- Reiterated total revenues guidance of $1.045 billion to $1.095 billion.
- Reiterated DAYBUE net product sales guidance of $380 million to $405 million.
- Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in early Q4 2025.
- Seven Phase 2 or Phase 3 studies expected to initiate during 2025-2026.
Challenges Ahead
- No specific negative forward guidance points were highlighted in the provided text.
- The increase in pre-tax income was more than offset by a higher effective tax rate, largely driven by reduced utilization of tax credits and net operating loss carryforwards under U.S. GAAP.
- No other explicit negative forward guidance points were mentioned.
- No other explicit negative forward guidance points were mentioned.
- No other explicit negative forward guidance points were mentioned.